down arrow

vTv Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US9183852048
USD
27.37
2.13 (8.44%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

25.9827.68

52 Week

13.1533.16
Valuation
Technical
Day's Volume

CASH

8.52 k

Shareholding (Mar 2025)

FII

0.10%

Held by 4 FIIs

DII

82.79%

Held by 9 DIIs

Promoter

7.92%

How big is vTv Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, vTv Therapeutics, Inc. has a market capitalization of 50.23 million and reported net sales of 0.02 million with a net profit of -22.91 million over the last four quarters. Shareholder's funds are 12.20 million, and total assets amount to 38.27 million.

As of Jun 18, vTv Therapeutics, Inc. has a market capitalization of 50.23 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 0.02 million, while the sum of net profit for the same period is -22.91 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 12.20 million, and total assets amount to 38.27 million.

Read More

What does vTv Therapeutics, Inc. do?

22-Jun-2025

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing orally administered small molecule drug candidates. It has a market cap of $50.23 million and reported a net profit loss of $6 million as of March 2025.

Overview:<BR>vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -6 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 50.23 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -3.91 <BR>Return on Equity: -291.62% <BR>Price to Book: 6.34<BR><BR>Contact Details:<BR>Address: 3980 Premier Dr, Suite 310, HIGH POINT NC: 27265 <BR>Tel: 1 336 8410300 <BR>Fax: 1 336 8410310 <BR>Website: http://vtvtherapeutics.com/

Read More

Who are in the management team of vTv Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of vTv Therapeutics, Inc. includes Executive Chairman Ms. Robin Abrams and Board members Mr. Hersh Kozlov, Mr. Richard Nelson, Mr. John Fry, Mr. Noel Spiegel, and Dr. Howard Weiner.

As of March 2022, the management team of vTv Therapeutics, Inc. includes Ms. Robin Abrams, who serves as the Executive Chairman of the Board. Additionally, the Board of Directors comprises Mr. Hersh Kozlov, Mr. Richard Nelson, Mr. John Fry, Mr. Noel Spiegel, and Dr. Howard Weiner, all of whom hold various director positions, with some serving as independent directors.

Read More

Is vTv Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of May 15, 2025, vTv Therapeutics, Inc. is assessed as overvalued with a valuation grade of "does not qualify" due to poor financial metrics, including a price-to-book ratio of 6.58, negative EV to EBIT and EV to EBITDA ratios, and a return on equity of -291.62%, significantly underperforming against the S&P 500.

As of 15 May 2025, the valuation grade for vTv Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial health. The company appears to be overvalued given its current metrics, with a price-to-book value of 6.58 and negative ratios for EV to EBIT and EV to EBITDA at -0.85. Additionally, the return on equity (ROE) is alarmingly low at -291.62%, reflecting severe inefficiencies in generating profit from equity.<BR><BR>In comparison to its peers, vTv Therapeutics shows a stark contrast, with Rezolute, Inc. and SELLAS Life Sciences Group, Inc. also classified as not qualifying, but with less extreme valuations of -4.90 and -5.73 for their respective EV to EBITDA ratios. The industry as a whole is struggling, but vTv's metrics suggest it is particularly vulnerable. Furthermore, the stock has underperformed significantly against the S&P 500 over various time frames, including a 1-year return of -19.38% compared to the index's 10.26%. Overall, vTv Therapeutics is assessed as overvalued in the current market environment.

Read More

Is vTv Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, vTv Therapeutics, Inc. shows a mildly bullish trend supported by positive MACD and Bollinger Bands, despite mixed signals from daily moving averages and underperformance over longer periods.

As of 8 September 2025, the technical trend for vTv Therapeutics, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, supporting the positive outlook. Bollinger Bands are bullish on both weekly and monthly time frames. The KST is mildly bullish on both weekly and monthly as well, indicating some upward momentum. However, the daily moving averages are mildly bearish, which presents a mixed signal. The stock has outperformed the S&P 500 significantly over the past week (6.42% vs. 1.05%) and month (37.56% vs. 2.33%), but it has underperformed over longer periods, particularly the 3-year and 5-year returns. Overall, the current technical stance is mildly bullish, driven primarily by the MACD and Bollinger Bands.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 60 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-9.36

stock-summary
Return on Equity

-868.94%

stock-summary
Price to Book

21.70

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-7 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
45.05%
0%
45.05%
6 Months
67.91%
0%
67.91%
1 Year
67.71%
0%
67.71%
2 Years
125.83%
0%
125.83%
3 Years
3237.8%
0%
3237.8%
4 Years
-39.98%
0%
-39.98%
5 Years
-67.26%
0%
-67.26%

vTv Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is vTv Therapeutics, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for vTv Therapeutics, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, supporting the positive outlook. Bollinger Bands are bullish on both weekly and monthly time frames. The KST is mildly bullish on both weekly and monthly as well, indicating some upward momentum. However, the daily moving averages are mildly bearish, which presents a mixed signal. The stock has outperformed the S&P 500 significantly over the past week (6.42% vs. 1.05%) and month (37.56% vs. 2.33%), but it has underperformed over longer periods, particularly the 3-year and 5-year returns. Overall, the current technical stance is mildly bullish, driven primarily by the MACD and Bollinger Bands....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0.00%
EBIT Growth (5y)
-2.76%
EBIT to Interest (avg)
-21.61
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-3.91
Sales to Capital Employed (avg)
0.03
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
23.10%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
6.58
EV to EBIT
-0.85
EV to EBITDA
-0.85
EV to Capital Employed
-0.92
EV to Sales
21.18
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-291.62%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 5 Schemes (9.2%)

Foreign Institutions

Held by 4 Foreign Institutions (0.1%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -19.35% vs -40.91% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.70",
          "val2": "-6.50",
          "chgp": "-18.46%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.10",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.40",
          "val2": "-6.20",
          "chgp": "-19.35%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 12.69% vs -3.59% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-24.10",
          "val2": "-25.40",
          "chgp": "5.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.10",
          "val2": "-4.00",
          "chgp": "97.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-22.70",
          "val2": "-26.00",
          "chgp": "12.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-23,775.80%",
          "val2": "0.00%",
          "chgp": "-2,377.58%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-7.70
-6.50
-18.46%
Interest
0.00
0.00
Exceptional Items
0.10
-0.00
Consolidate Net Profit
-7.40
-6.20
-19.35%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -19.35% vs -40.91% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
1.00
0.00
Operating Profit (PBDIT) excl Other Income
-24.10
-25.40
5.12%
Interest
0.00
0.00
Exceptional Items
-0.10
-4.00
97.50%
Consolidate Net Profit
-22.70
-26.00
12.69%
Operating Profit Margin (Excl OI)
-23,775.80%
0.00%
-2,377.58%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 12.69% vs -3.59% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About vTv Therapeutics, Inc. stock-summary
stock-summary
vTv Therapeutics, Inc.
Pharmaceuticals & Biotechnology
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.
Company Coordinates stock-summary
Company Details
3980 Premier Dr, Suite 310 , HIGH POINT NC : 27265
stock-summary
Tel: 1 336 8410300
stock-summary
http://vtvtherapeutics.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."